IP Library Granted Patent US 12,163,162
Granted Patent B2
US 12,163,162 · App. 18/164,522 · Granted Dec 10, 2024

Biocatalysts and methods for the synthesis of substituted lactams

Inventors: Fabien Louis Cabirol (Dusseldorf, DE); Haibin Chen (Beijing, CN); Anupam Gohel (Bekasi, ID); Paulina Elena Salim (Singapore, SG); Derek J. Smith (Singapore, SG); Jacob Janey (New York, NY); Birgit Kosjek (Westfield, NJ); Weng Lin Tang (Singapore, SG); Helen Hsieh (Singapore, SG); Son Q. Pham (Singapore, SG)
Assignee: Codexis, Inc.
C12N9/1096C07D211/76C12P13/001C12P13/005C12P17/12C12Y206/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,163,162
App. No.
18/164,522
Granted
Dec 10, 2024
Kind
B2
Abstract

The present disclosure relates to transaminase polypeptides capable of aminating a dicarbonyl substrate, and polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides.

Claims (20)

1. An engineered transaminase polypeptide comprising an amino acid sequence having at least 80% sequence identity to reference sequence SEQ ID NO: 4 and at least an amino acid residue difference as compared to SEQ ID NO:4 at residue position X136 is L, and wherein the amino acid residue at residue position X284 is selected from A, G, P, S, T, or V.

2. The engineered transaminase polypeptide of claim 1 , wherein the amino acid sequence further comprises one or more residue differences as compared to SEQ ID NO: 4 selected from: X42G; X54P; X54R; X69A; X69G; X69T; X122M; X124F; X124L; X124N; X124R; X126A; X126T; X150S; X152C; X152G; X152I; X152L; X152S; X156A; X156S; X156T; X157L; X165N, X192A, X192G, X192H, X192K, X192N, X192Q, X192R, and X192S.

3. The engineered transaminase polypeptide of claim 1 , wherein the amino acid sequence further comprises a combination of residue differences selected from:

(a) X124W and X327L;

(b) X209M and X300G;

(c) X122F and X223V;

(d) XI92A, X215H and X311T;

(e) X62N, X124F, and X126A;

(f) X124W, X126A, and X192A; and

(g) X124W, X126A, X152R/X152L/X152I, and X192A.

4. The engineered transaminase polypeptide of claim 1 , in which the amino acid sequence further comprises at least one or more residue differences as compared to SEQ ID NO: 4 selected from: X54A; X54L; X56D; X56E; X61G; X61W; X62A; X62L; X62N; X62S; X64C; X68I; X122F, X122W; X122Y; X124K; X124M; X124S; X124W; X126C; X126I; X139E; X140K; X143V; X150L; X155I; X155L; X159G; X160L; X176C; X199L; X199V; X209F; X209M; X209Q; X209V; X223S; X223T; X223V; X227I; X282L, and X282V.

5. The engineered transaminase polypeptide of claim 1 , wherein said polypeptide is purified.

6. A composition comprising the engineered transaminase polypeptide of claim 1 .

7. An engineered polynucleotide encoding the engineered transaminase polypeptide of claim 1 .

8. A vector comprising the engineered polynucleotide of claim 7 .

9. A host cell comprising the vector of claim 8 .

10. The host cell of claim 9 , wherein said host cell is an Escherichia coli cell.

11. The vector of claim 8 , further comprising at least one control sequence.

12. A host cell comprising the vector of claim 11 .

13. The host cell of claim 12 , wherein said host cell is an Escherichia coli cell.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (7)
Division 17087484 · Nov 2, 2020
Division 16825641 · Mar 20, 2020
Division 15449677 · Mar 3, 2017
Division 14799180 · Jul 14, 2015
Division 14342713
Provisional Application 61532259 · Sep 8, 2011
Related Publication 20230313155A1 · Oct 5, 2023